Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

被引：0
|
作者：
Carmen M. Labandeira
Maria G. Alonso Losada
Rosa Yáñez Baña
Maria I. Cimas Hernando
Iria Cabo López
Jose M. Paz González
Maria J. Gonzalez Palmás
Cristina Martínez Miró
Diego Santos García
机构：
[1] CHUVI,Department of Clinical Neurology
[2] Complejo Hospitalario Universitario de Vigo,undefined
[3] CHUO,undefined
[4] Complejo Hospitalario Universitario de Ourense,undefined
[5] Hospital de Povisa,undefined
[6] CHOP,undefined
[7] Complejo Hospitalario Universitario de Pontevedra,undefined
[8] CHUAC,undefined
[9] Complejo Hospitalario Universitario de A Coruña,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Safinamide; Non-motor symptoms; Parkinson’s disease; Depression; Mood;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5398 / 5411
页数：13
相关论文
共 50 条
  • [41] Evaluation of open-label rotigotine treatment in advanced Parkinson's disease
    Lyons, K. E.
    Pahwa, R.
    Boroojerdi, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 118 - 118
  • [42] Evaluation of open-label rotigotine treatment in advanced Parkinson's disease
    Lyons, K. E.
    Pahwa, R.
    Boroojerdi, B.
    MOVEMENT DISORDERS, 2008, 23 (01) : S215 - S215
  • [43] Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes
    Hui, Jennifer S.
    Fox, Susan H.
    Neeson, William
    Bhargava, Parul
    Pappert, Eric
    Blum, David
    Navia, Bradford
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : 110 - 116
  • [44] Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial
    Kim, Aryun
    Kim, Young Eun
    Yun, Ji Young
    Kim, Han-Joon
    Yang, Hui-Jun
    Lee, Woong-Woo
    Shin, Chae Won
    Park, Hyeyoung
    Jung, Yu Jin
    Kim, Ahro
    Kim, Yoon
    Jang, Mihee
    Jeon, Beomseok
    JOURNAL OF MOVEMENT DISORDERS, 2018, 11 (02) : 65 - 71
  • [45] Effectiveness and Safety of Donepezil in Hispanic Patients with Alzheimer's Disease: A 12-Week Open-Label Study
    Lopez, Oscar L.
    Mackell, Joan A.
    Sun, Yijun
    Kassalow, Laurent M.
    Xu, Yikang
    McRae, Thomas
    Li, Honglan
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2008, 100 (11) : 1350 - 1358
  • [46] An open-label investigation of lamotrigine in Parkinson's patients with motor fluctuations
    Reider, CR
    Rienerth, JED
    Hubble, JP
    Paulson, GW
    NEUROLOGY, 1998, 50 (04) : A279 - A279
  • [47] Open label study of cannabidiol in Parkinson's disease
    Leehey, M.
    Liu, Y.
    Epstein, C.
    Hart, F.
    Bainbridge, J.
    Cook, M.
    Sillau, S.
    Baud, Z.
    Newman, H.
    MOVEMENT DISORDERS, 2017, 32
  • [48] Selegiline improves excessive daytime sleepiness in Parkinson’s disease: an open-label observational study
    Zhang Jinru
    Chen Juping
    Li Jia
    Li Jian
    Miao Hong
    Zhu Xiangyang
    Meng Meng
    Han Yang
    Chen Jing
    Cheng Xiaoyu
    Xiong Kangping
    Jin Hong
    Luo Weifeng
    Mao Chengjie
    Liu Chunfeng
    中华医学杂志英文版, 2022, 135 (14) : 1762 - 1764
  • [49] SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study
    Dell'Agnello, G
    Ceravolo, R
    Nuti, A
    Bellini, G
    Piccinni, A
    D'Avino, C
    Dell'Osso, L
    Bonuccelli, U
    CLINICAL NEUROPHARMACOLOGY, 2001, 24 (04) : 221 - 227
  • [50] Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Stocchi, F.
    Antonini, A.
    Moreira, J.
    Guimaraes, B.
    Rocha, J. F.
    MOVEMENT DISORDERS, 2023, 38 : S22 - S23
12345